CN Patent

CN101395170A — 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物

Assigned to Intercept Pharmaceuticals Inc · Expires 2009-03-25 · 17y expired

What this patent protects

本发明涉及用于治疗FXR介导的疾病或状态的式(I)化合物及其药物可接受的盐、溶剂合物或氨基酸偶联物，其中，R 1 为氢或烷基；R 2 为氢或卤素、硝基、烷氧基、氨基或羧基；Y为CH 2 、氧或硫；n为1－4的整数。

USPTO Abstract

本发明涉及用于治疗FXR介导的疾病或状态的式(I)化合物及其药物可接受的盐、溶剂合物或氨基酸偶联物，其中，R 1 为氢或烷基；R 2 为氢或卤素、硝基、烷氧基、氨基或羧基；Y为CH 2 、氧或硫；n为1－4的整数。

Drugs covered by this patent

Patent Metadata

Patent number
CN101395170A
Jurisdiction
CN
Classification
—
Expires
2009-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Intercept Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.